Compare iShares Russell 2000 ETF (IWM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Medpace Holdings Inc — how do they compare? iShares Russell 2000 ETF trades at $278.89 (market cap $77.70B), while Medpace Holdings Inc trades at $617.27 (market cap $16.82B). The key difference: iShares Russell 2000 ETF is far larger — about 4.6× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, iShares Russell 2000 ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Medpace Holdings Inc for 14 Days on average.
| IWM | MEDP | |
|---|---|---|
Market Cap | $77.70B | $16.82B |
Volume | 35,598,983 | 223,093 |
52-Week High | $305.06 | $630.19 |
52-Week Low | $229.13 | $393.42 |
Typical Hold Time | 83 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $278.05, up 0.12% with bearish technical signals from moving averages. The small-cap ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices. Recent news highlights IWM's decade-long trailing of the S&P 500 while carrying higher risk, with institutional selling pressure evident from Envestnet's 4.6% stake reduction in Q3 2026.
Small-cap exposure offers diversification but faces near-term pressure from tightening financial conditions. The ETF's broad Russell 2000 composition includes unprofitable companies, creating performance drag. Upside potential exists if economic conditions improve, but current momentum favors large-caps amid rising interest rates and energy price volatility.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
